LYCOS RETRIEVER 
Guidant
built 647 days ago
Guidant is not, this time, recommending against surgery to replace these two models. It is not making a recommendation one way or the other. It is urging physicians to closely follow how well the two models are functioning. This urging is apparently purely a result of the Times's exposure of the issue. (Note that the death involving a Renewal malfunction was only reported to Guidant on May 30. But there were ... 14 earlier reports of electrical failures with Renewal units.)
Source:
The situation for Guidant may not be as bad as it appears. It’s not clear whether criminal investigators have actually joined the FDA to probe how Guidant reported problems with the heart devices and the efforts to fix them.
Source:
As of July 11, 2005, Guidant has identified sixty-nine (69) devices that may have exhibited this failure mode from approximately 78,000 devices distributed with this component. While no failures have been reported prior to 44 months of service, the likelihood of occurrence increases with implant time. Guidant's modeling based on field experience and statistical life-table analysis predicts the rate of failure in the remaining active implanted devices to be between 0.17% and 0.51% over the remaining device lifetime. Of the 78,000 devices originally distributed, approximately 28,000 devices remain implanted worldwide; 18,000 of these devices remain in service in the United States with an average implant age of 69 months.
Source:
In 2003, Guidant had five FAMU interns and made offers to four of them. "We're starting to send the message internally to our organization that there's some terrific talent available at FAMU," says Carlisle.
Source:
On November 7, Guidant sued Johnson & Johnson to force them to complete the deal. On November 15, the two companies announced a renegotiated purchase price of $63 a share, or $21.5 billion, a 15% price reduction. On December 5th, 2005, Boston Scientific made a surprise unsolicited $24.6 billion bid to acquire Guidant, offering $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share. Guidant's stock price rose 10% on the news. The offer was not actually finalized until after due diligence had been completed on January 8, 2006.
Source:
In addition, Guidant appears to have fully complied with the Food and Drug Administration's reporting regulations. It filed reports of individual problems with the device as it received them, and it reported the second of two manufacturing changes it made in 2002. (The company says it did not report the first 2002 change because it decided that F.D.A. regulations did not require the reporting of those "manufacturing enhancements.")
Source:
MORE ABOUT
Guidant